Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stockhldr:
"He is not allowed to state that anything has changed..."
Then, why the mention the "lack of funding at all," is what bothers me.
Ann
Eureka:
"The comments in regards to "interest" from VC type investors refers to feedback from the different roadshows that DNAG has participated in"
No comments were ever posted on this board regarding interest from VC type investors...
The stockholders were kept in the dark on the subject matters you address - not all, but, most of them.
Ann
Eureka:
"Some of you may remember the plans to spilt the company were initiated in July of last year and Athena Capital had been working on structuring the deal."
I don't believe any such imformation was ever posted on this board.
Ann
Eureka:
"There has been some comments in regards to "interest" from potential VC type investors...etc."
Do you have some sort of insider information?
Ann
Stocky:
"I just wish M2GEN city vote would happen soon!"
At the moment we're not getting anywhere fast...but, hopefully, it WILL happen soon!
Take care,
Ann
What are you referring to Stockhld?
Take care,
Ann
DNAP - in line the ovarian cancer research:
DNAPrint Developing Ovarian Chemotherapy Response Test
In line with current trends in the microarray medical diagnostic market, DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) will soon start an analysis of its OVANOME predictive assay. The goal of the study is to further the development of a diagnostic test to determine if a specific ovarian cancer patient will elicit a positive response from Taxol-Carboplatin (TC) chemotherapy. According to the company, TC "elicits only a 70% positive response rate." Furthermore according to Hector J. Gomez, M.D., Ph.D., DNAPrint's Chief Medical Officer, "This study could lead to the development of a diagnostic test for predicting TC response, enabling physicians to identify patients most likely to respond to TC therapy prior to treatment. It could also spare non-responding patients from going through a treatment program that would not be effective in the first place."
Noting the seriousness of failed TC was Rafael Blanco, M.D., the principal investigator at Bay Area Oncology, "Patients who do not respond to first-line treatment for ovarian cancer exhibit higher mortality than those who do. Methods that allow the inference of a patient's reaction to treatment could enable those genetically predisposed for non-response to avoid a failed TC first-line and be treated immediately with an alternative therapy."
Ann
Semaphore's clients - DNAP -:
http://www.sema4usa.com/clients.htm
Ann
Ordering DNAP through Lynn Peavy:
DNAWitness Collection Kit (09596)
DNAPrint™ Genomics, Inc. introduces DNAWitness™. From a simple swabbing at the crime scene, the results will tell you the Biogeographical Ancestry (BGA) of an unknown sample.
Knowing the BGA of a sample tells you which direction to start looking…and more importantly, where not to. It may confirm that you’re on the right track, or that you’re barking up the wrong tree. It’ll tell you in precise detail if your suspect (or unknown victim) is European, East Asian, Native American, and Sub-Saharan African…all in less than two weeks!
Contents of the kit include: one PreZerve, one IntegriSwab, a request for service form, an integrity seal, and a FedEx envelope and airbill.
The DNAWitness Collection Kit is provided FREE! You only pay when you send it in for processing. The processing charge is $1,000.
Ann
This has to do with ovarian cancer testing DNAP's involved in...
large grant - IMO
Ann
Correction:
From National Cancer Institute
Ann
Moffit receives 7.3 million grant from NIH:
http://www.bizjournals.com/tampabay/stories/2007/04/02/daily5.html?from_rss=1
Ann
DNAG removed from SHO list - dated today - 5/1:
Stock:
Would a takeover be detrimental to the stockholders? Do you know?
Take care,
Ann
So sorry to hear, Gooch.
You take care and all the best to you.
Ann
An excert from Tony Frudakis' 1st shareholder newsletter:
When I speak at meetings with executives of other private and publicly held companies, I am continually amazed at how little effort they are putting into genetics IT and discovery. The reason for this is, that it’s hard, and hard things tend to get done last. Thus, any company that builds a system to solve genetics problems on a genomics scale is worth its’ weight in gold. At the close of year one, DNAPrint is about half way to having our informatics platform for solving these problems completed. We have developed 8 different software components of this platform, and filed patents covering their composition and use. For example, we have filed on a proprietary cladistics-based, geometric modeling scheme for identifying epistatic and dominance components of quantitative genetic variance. To our knowledge, there are no other programs like this anywhere in the world.
Ann
Johnny:
Obviously, I know the difference between the initials: DNA & DNAP. Just threw this article out for interest as it is such new news and DNAP is working in this area also. The article mentions working with SNPS, etc.
Take care,
Ann
Succinctly stated:
"Our test kits have performed nearly 45,000 tests on human DNA and we have spent significant time and effort to assure high standards in our testing. We are excited about applying our analysis to clinical trial patients in order to better understand diseases and to develop 'theranostic' test/drug combinations that will improve efficacy and reduce side effects."
Ann
Emory & DNAP clinical validations:
"Emory and DNAPrint are working together to bring the genetic ancestry data forward within a clinical environment," stated Richard Gabriel, President and Chief Executive Officer of DNAPrint Genomics.
"This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics," said Dr. Mark Bouzyk, Director of Emory's Center for Medical Genomics.
"Just analyzing random SNPs for associated genetic ancestry is meaningless, expensive and time consuming," said Dr. Tony Frudakis, Chief Scientific Officer and Founder of DNAPrint Genomics. "What is contained in this package kit are nearly six years of research and development related to our forensics technology. We are excited about applying our genetic ancestry data to understanding and hopefully improving disease treatment and drug development in a clinical regulated environment."
"We will assist Emory's scientific team to help them develop the necessary skills for running our rigorous testing, Quality Control and Quality Assurance protocols," said Dr. Matt Thomas, Senior Scientist and Manager of Laboratory Operations for DNAPrint Genomics. "Our test kits have performed nearly 45,000 tests on human DNA and we have spent significant time and effort to assure high standards in our testing. We are excited about applying our analysis to clinical trial patients in order to better understand diseases and to develop 'theranostic' test/drug combinations that will improve efficacy and reduce side effects."
Ann
On AOL News today - Anyone think of DNAP's involvement?
"New Genes Linked to Diabetes Found"
By LAURAN NEERGAARD
AP
WASHINGTON (April 26) - Scientists have found clusters of new gene variants that raise the risk of Type 2 diabetes - and how the researchers did it is as important as what they found.
In one of the largest studies yet of human genetic variability, the scientists tested the DNA of more than 32,000 people in five countries to pin down spots that harbor genetic risk factors for this complicated killer.
This type of research - called a "genome-wide association" study - promises to usher in a new era of genetics. Most breakthroughs so far have come from finding a mutation in a single gene that causes illness. But some of the world's most common killers, such as heart disease and diabetes, are caused by complex interactions among numerous genes and modern lifestyles - and teasing out the genetic culprits until now has been almost impossible.
"We have been for all of the last decade or more looking under the lamppost to try to find those genes ... and lots of times the lamplight was not actually where we wanted it," said Dr. Francis Collins, genetics chief at the National Institutes of Health, a co-author of the research unveiled Thursday.
This new approach "allows us to light up the whole street, and look what we find."
What? Four previously unknown gene variants that can increase people's risk of Type 2 diabetes, and confirmation that six other genes play a role, too.
The work, by three international research teams that shared their findings, was published online Thursday by the journal Science.
Also Thursday in the journal Nature Genetics, another team led by Iceland researchers reported separately finding one of those same new genes - and that, interestingly, it seems to increase the diabetes risk most in people who aren't obese.
Next, the researchers will have to figure out just what those genes do, in hopes they'll point toward new ways to treat or prevent a disease that affects more than 170 million people worldwide, and rising.
With Type 2 diabetes, the body gradually loses its ability to use insulin, a hormone key for turning blood sugar into insulin. It is a major cause of heart disease, as high blood sugar damages blood vessels, and leads to kidney failure, blindness and amputations.
Obesity and lack of exercise are chief risk factors. But heredity is involved, too: People with an affected parent or sibling are at 3.5 times greater risk of developing diabetes than people from diabetes-free families.
The new work scanned DNA to find patterns of small gene variations known as SNPs (pronounced "snips") more common in diabetics. SNPs can serve as signposts for tracing disease-promoting genes. To be certain the implicated SNPs were involved, the researchers then checked for them in still more volunteers, ultimately testing DNA from 32,500 people in Britain, Finland, Poland, Sweden and the U.S.
The highest-risk variants can increase by 20 percent someone's odds of developing Type 2 diabetes, the teams reported.
Ann
Gabriel said he believes investors' concern about the safety of anti anemia drugs will be temporary.
"The reality of [erythropoietin] is it saves a lot of lives and improves the lives of a lot of people. Otherwise, it wouldn't be a $12 billion a year drug," Gabriel said.
Sytkowski, who holds eight patents on super epo, would be entitled to 30 percent of the royalty fees under Beth Israel Deaconess's distribution schedule.
Ann
Plans for anemnia drug runs into....
http://www.boston.com/business/technology/biotechnology/articles/2007/04/09/plans_for_anemia_drug_ru...
Ann
Just a notch under our gunbelt:
http://www.sys-con.com/read/246947.htm
Ann
Ellipses corporate profile:
Hector Gomez, M.D., Ph.D. | Chair
Dr. Gomez has over twenty years of experience in the biopharmaceutical industry and has managed the development of 10 marketed drugs, mostly in the cardiovascular area. Dr. Gomez has previously served as President and CEO of Transcend Therapeutics, Inc., CEO of Zengen, Inc., Vice President of Medical Affairs for Vertex Pharmaceuticals and as an Executive Director with Ciba-Geigy Corporation. From 1979 to 1988 Dr. Gomez was a Director and Senior Director at Merck/MSDRL Corporation. He currently serves as the Chairman of the Board of Directors of DNAPrint™ genomics, Inc., PRB Pharmaceuticals, Inc. and Asia Healthcare Ltd. Dr. Gomez received an M.D. from the National University of Colombia, a Ph.D. from Marquette University, and a Diploma in Clinical Pharmacology from Tulane University.
Tony Frudakis, Ph.D.
Dr. Frudakis founded GAFF biologic, the predecessor in interest to DNAPrint™ genomics, Inc., in 1998. He served as its President and Chief Executive Officer. Prior to founding GAFF biologic, Dr. Frudakis was a research scientist for Corixa Corporation for four years. While at Corixa he developed several new techniques for RNA fingerprinting, managed and executed high-throughput gene discovery programs for various cancers and was instrumental in the company's early success in attracting research and development partners. In all, his work has resulted in a patent portfolio for over 350 unique genes and two products. Dr. Frudakis is a Phi Beta Kappa, Magna cum laude graduate of the University of California Irvine where he received a BS degree in Biological Sciences. Dr. Frudakis also earned a doctorate degree in molecular and cell biology from the University of California Berkeley.
Ann
About Ellipses:
Ellipsis Biotherapeutics Corporation provides commercial genotyping services, including research capabilities for development of novel genetic tests and gene discovery. It was incorporated in Ontario, Canada, in 1997.
As part of its founding mission to investigate genetic susceptibility to inflammatory disease, Ellipsis established fully automated high throughput SNP analysis capabilities. Ellipsis has leveraged this core expertise in human disease research and genetic analysis to provide superior quality genotyping services to government, academic and industrial clients.
Ellipsis provides a wide range of SNP services using state-of-the-art technologies. With these platforms, Ellipsis can support customers throughout the entire progression of their SNP studies.
With the focused objective of providing high quality SNP genotyping to the marketplace and the commitment of dedicated resources, Ellipsis delivers quality and accurate results rapidly, translating to faster turn-around times and higher value results for our customers.
Ann
Aw!
Altar, keep "clicking those beads!" - lol
Ann
David...you seem like a very nice and cordial person.
I wonder when we'll get the notice for the shareholder's meeting? My guess is sometime in May.
Take care,
Ann
Thanks, Bag...
Have a nice one, as always
Ann
DNAP Consulting for Ancestrybydna:
http://dnaconsultants.com/Detailed/12.html
Ann
DNAPrint's Europe DNA:
http://dnaconsultants.com/Detailed/7.html
Ann
Focus of the conference:
1) WINNERS ONLY!
Wall Street Reporter is focused on WINNERS!
We only interview companies making good news - new products and services, record profits and sales growth, breakthrough developments, etc. The companies interviewed in Wall Street Reporter are the leaders driving the world economy, and creating shareholder wealth.
Each day Wall Street Reporter brings you companies with the fundamental ingredients for explosive stock price appreciation.
Wall Street Reporter only interviews companies making positive news announcements - and progress! These are tomorrow�s great companies - today.
Ann
DNAPrint attending this conference:
http://www.wallstreetreporter.com/sdc/
Ann
The applications:
Tandy Herren, PhD, was named director of simulation technology and Neil Kabrun, PhD, director of biological modeling. Herren will be responsible for applying DNAPrint's proprietary BioFusion simulation technology, as well as other modeling techniques to support the company's drug and diagnostics product development programs. Kabrun is responsible for the acquisition and implementation of a toolbox of techniques and systems that will continue to advance the role of computational methods in improving product development.
Ann
"DNAPrint Pharmaceuticals is pleased to have attracted two experienced scientists in this important new field of computational biology," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and head of the DNAPrint Pharmaceuticals subsidiary. "We are committed to the value that computational biology brings to our drug and diagnostic development programs."
Ann
DNAP appoints two key technologists at DNAP:
http://findarticles.com/p/articles/mi_pwwi/is_200605/ai_n16409995
Ann
More on advancements on PT-401:
http://www.genengnews.com/news/bnitem.aspx?name=15237453&taxid=0
Ann
Advancements in PT-401:
http://www.hirehealth.com/Public/NewsDetails.aspx?NEWS_ID=51302
Ann
More on Neil Kobrun:
http://www.marketwire.com/mw/release_html_b1?release_id=129996
Ann
Anaheim, CA convenion by DNAP:
http://www.dnaprint.com/welcome/press/press_recent/2007/0404/DNAG-PAPERS-review.pdf
Ann